Duvelisib attenuates bleomycin‐induced pulmonary fibrosis via inhibiting the <scp>PI</scp>3<scp>K</scp>/Akt/m<scp>TOR</scp> signalling pathway

Xiaohe Li, Xiaoyang Ma, Miao Yang, Jianwei Zhang, Buri Xi, Wenqi Li, Qianyi Zhang, Li Chen, Yue Yang, Hongli Li, Luqing Wei, Honggang Zhou, Cheng YangJournal of Cellular and Molecular Medicine 2023 · DOI

TL;DR

This study investigates Duvelisib, a PI3K inhibitor, as a potential treatment for idiopathic pulmonary fibrosis (IPF). Researchers found that Duvelisib effectively reduced fibrosis in a mouse model and suppressed key pro-fibrotic processes in lung fibroblasts by inhibiting the PI3K/Akt/mTOR pathway, suggesting it could be a promising therapeutic agent for IPF.

What Problem Does This Paper Address?

Idiopathic pulmonary fibrosis (IPF) is a severe, progressive lung disease with unclear causes and limited effective treatments. A key feature of IPF is the excessive activation of myofibroblasts, cells that lead to the abnormal deposition of extracellular matrix (ECM) in the lungs, ultimately impairing lung function and leading to respiratory failure. The PI3K/Akt/mTOR signaling pathway is known to play a crucial role in promoting fibroblast activation and hindering autophagy (a cellular "clean-up" process) in lung fibrosis. Therefore, targeting this pathway presents a potential therapeutic strategy. Duvelisib, an existing drug approved for certain blood cancers, is a dual inhibitor of PI3K-δ and PI3K-γ. This research explores whether Duvelisib's known mechanism of action could be leveraged to treat pulmonary fibrosis.

Methods

The study employed a multi-pronged approach:

  • In vivo studies: A standard mouse model of bleomycin-induced pulmonary fibrosis was used. Mice were treated with varying doses of Duvelisib, a positive control (Nintedanib), or a vehicle. Lung function was assessed using plethysmography, and lung tissues were analyzed for collagen content (hydroxyproline assay), fibrosis severity (histological examination with H&E and Masson's trichrome staining), and protein expression of key fibrotic markers (Western blot, immunohistochemistry).
  • In vitro studies: Primary mouse lung fibroblasts (Mlg and PPF cells) were used to investigate the cellular mechanisms. These cells were stimulated with TGF-β1, a known inducer of fibrosis, and then treated with Duvelisib. Techniques included:
  • MTT and CCK-8 assays: To assess cell viability and proliferation.
  • EdU assay: To measure DNA synthesis and thus cell proliferation.
  • Wound healing assay and Transwell assay: To evaluate fibroblast migration.
  • Western blot analysis: To measure the protein levels and phosphorylation status of key signaling molecules (PI3K, Akt, mTOR) and autophagy markers (LC3, p62).
  • Quantitative real-time PCR (qRT-PCR): To assess gene expression levels of fibrotic markers (α-SMA, fibronectin).
  • Immunofluorescence staining: To visualize the expression of α-SMA in cells.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • Duvelisib as a repurposed drug: The study highlights the potential of repurposing Duvelisib, an existing drug for blood cancers, for treating pulmonary fibrosis. This approach can significantly accelerate drug development by leveraging existing safety and pharmacokinetic data.
  • Targeting the PI3K/Akt/mTOR pathway is key: The research strongly implicates the PI3K/Akt/mTOR pathway as a central player in both fibroblast activation and impaired autophagy in pulmonary fibrosis. Duvelisib's ability to inhibit this pathway appears to be the core of its therapeutic effect.
  • Dual action on fibrosis and autophagy: Duvelisib not only suppresses fibroblast activation (proliferation, migration, and differentiation) but also appears to restore autophagy, a process often dysregulated in IPF. This dual action is crucial for effectively combating the disease.
  • In vivo efficacy mirrors in vitro findings: The study demonstrates a consistent effect of Duvelisib across both animal models and cell culture experiments, strengthening the evidence for its therapeutic potential.

Key Results

  • In vivo: Duvelisib treatment significantly reduced collagen deposition and improved pulmonary function in bleomycin-induced fibrotic mice. The high-dose Duvelisib showed comparable or better effects than the positive control, Nintedanib.
  • In vitro:
    • Duvelisib inhibited TGF-β1-induced proliferation, migration, and activation (α-SMA and fibronectin expression) of lung fibroblasts in a dose-dependent manner.
  • Duvelisib treatment restored autophagy, evidenced by increased LC3II/I ratio and decreased p62 levels.
  • Duvelisib significantly suppressed the phosphorylation of PI3K, Akt, and mTOR in both Mlg and PPF cells.
  • In vivo signaling: Western blot analysis of lung tissues from BLM-treated mice showed that Duvelisib inhibited the BLM-induced phosphorylation of PI3K, Akt, and mTOR.

Limitations and Future Work

  • Animal model limitations: While the bleomycin-induced model is standard, it doesn't fully replicate the complexity of human IPF, which often arises from repeated injuries. The study acknowledges that the model represents acute inflammation and fibrosis, and the 14-day time point was chosen for optimal variability.
  • Mechanism of PI3K isoform specificity: The paper mentions Duvelisib inhibits PI3K-δ and PI3K-γ. While studies suggest these isoforms are expressed in lung fibroblasts, further detailed investigation into the specific contribution of each isoform to fibrosis and Duvelisib's action could be beneficial.
  • Clinical translation: The study successfully demonstrates Duvelisib's efficacy in preclinical models. The authors suggest that Duvelisib is promising for IPF treatment and has entered clinical trials for other conditions, implying a clear path for future clinical investigation in IPF. Further studies could explore optimal dosing regimens and long-term safety in the context of pulmonary fibrosis.

Summary updated

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive interstitial lung disease that seriously threatens the health of patients. The pathogenesis of IPF is still unclear, and there is a lack of effective therapeutic drugs. Myofibroblasts are the main effector cells of IPF, leading to excessive deposition of extracellular matrix (ECM) and promoting the progression of fibrosis. Inhibiting the excessive activation and relieving autophagy blockage of myofibroblasts is the key to treat IPF. PI3K/Akt/mTOR pathway plays a key regulatory role in promoting fibroblast activation and autophagy inhibition in lung fibrosis. Duvelisib is a PI3K inhibitor that can simultaneously inhibit the activities of PI3K-δ and PI3K-γ, and is mainly used for the treatment of relapsed/refractory chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma tumour (SLL). In this study, we aimed to examine the effects of Duvelisib on pulmonary fibrosis. We used a mouse model of bleomycin-induced pulmonary fibrosis to evaluate the effects of Duvelisib on pulmonary fibrosis in vivo and further explored the potential pharmacological mechanisms of Duvelisib in lung fibroblasts in vitro. The in vivo experiments showed that Duvelisib significantly alleviated bleomycin-induced collagen deposition and improved pulmonary function. In vitro and in vivo pharmacological experiments showed that Duvelisib dose-dependently suppressed lung fibroblast activation and improved autophagy inhibition by inhibiting the phosphorylation of PI3K, Akt and mTOR. Our results indicate that Duvelisib can alleviate the severity of pulmonary fibrosis and provide potential drugs for the treatment of pulmonary fibrosis.
BibTeX
@article{li2023duvelisib,
  author = {Xiaohe Li and Xiaoyang Ma and Miao Yang and Jianwei Zhang and Buri Xi and Wenqi Li and Qianyi Zhang and Li Chen and Yue Yang and Hongli Li and Luqing Wei and Honggang Zhou and Cheng Yang},
  title = {{Duvelisib attenuates bleomycin‐induced pulmonary fibrosis via inhibiting the <scp>PI</scp>3<scp>K</scp>/Akt/m<scp>TOR</scp> signalling pathway}},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2023},
  doi = {10.1111/jcmm.17665},
}
Figure